Gyrolab® Bioaffy™ 200
Gyrolab® Bioaffy™ 200, the most versatile disc in the Bioaffy range, with 112 data points and 200 nL sample volume this disc fits many different applications.
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
Gyrolab® Bioaffy™ 200 disc enables immunoassays to be run in an affinity-column format using streptavidin-coated beads at nanoliter-scale. Engineered with highly reproducible microfluidic structures that ensure high-precision volume definition and tight control over the workflow. Precise, and automated control of centrifugal forces and capillary actions steer liquid flow through the 112 microfluidic structures within the disc. The flow-through affinity micro-column format eliminates incubations and minimizes matrix interference. The nanoliterscale format saves reagents and samples. The result is cost effective and highly reproducible data over a road dynamic range.
Your guide to miniaturized immunoassays for biotherapeutics
Building on advances in microfluidics, next-generation immunoassays offer unparalleled capability in automation and miniaturization, generating robust and reproducible results for faster decision-making.
In this eBook, discover the advantages of automated, miniaturized immunoassays across the drug development pathway, from pre-clinical to bioprocessing. Learn about challenges and trends in immunoassay technology and how automated, miniaturized immunoassays can help you maximize productivity across a range of biopharmaceutical applications, including:
- Research and clinical development
- Insulin quantification
- Anti-drug antibody studies
- In-solution affinity determination
- Vaccine development and production
One-hour, microfluidic SARS-CoV-2 antibody immunoassay
In this white paper, Gyros Protein Technologies demonstrates how high-quality reagents from Sino Biological can be used in a high-performance, one-hour microfluidic, nanoliterscale immunoassay using Gyrolab® platform for the qualitative detection of total antibodies generated against the receptor binding domain (RBD) of the spike protein of SARS-CoV-2 in human serum samples.
Download it below to explore details of the miniaturized, microfluidic SARS-CoV-2 antibody immunoassay development and learn more about the future directions for Gyrolab assay development to detect SARS-CoV-2 antibodies.
Inside Gyrolab Bioaffy CD: Seamless transfer of immunoassays
In this video, Gyros Protein Technologies demonstrates how Gyrolab® Bioaffy™ CDs enable seamless assay transfer with precision and reproducibility. Learn how the proprietary CD technology, engineered with highly reproducible nanoliter microfluidics, simplifies assay workflows by eliminating incubations and shortening run times.
Gyros Protein Technologies and Cygnus Technologies collaborate to support bioprocess impurity analytics
The Collaboration is poised to deliver a range of ready-to-use bioprocess impurity reagent sets
